Christopher Cheng, PhDAssociate Director Formulation Technology Development at Casebia Therapeutics
My philosophy toward developing RNA-based therapeutics is to continually improve how and what we understand of these complex systems. I take a holistic approach toward RNA formulation development, which includes optimization of the RNA payloads, the carriers, and their interactions utilizing analytical and functional in vivo characterization. I currently lead the nanoformulation and mRNA development group at Casebia therapeutics with an emphasis on developing liver-targeted gene editing medicines. Previously I led the Nucleic Acid Technology group at Alexion Pharmaceuticals, where I focused on formulation and process development of various nucleic acid modalities including mRNA therapeutics, RNAi, and antisense. I performed my PhD and postdoctoral research at Yale University, where I had interdisciplinary training in Molecular Biophysics & Biochemistry, Biomedical Engineering, Drug Delivery, and RNA Molecular Biology.